Corcept Therapeutics
Corcept Therapeutics Inc is an American commercial-stage pharmaceutical enterprise headquartered in Menlo Park, California. The company focuses on the discovery, development, and commercialization of innovative medications that treat severe endocrine, oncological, and metabolic disorders by modulating cortisol activity through receptor antagonism. Its clinical portfolio is anchored by proprietary selective cortisol modulators. Principal revenue is derived through commercial sales of its flagship pharmaceutical products to healthcare providers and specialty pharmacies. Corcept Therapeutics Inc is publicly listed on the Nasdaq Stock Market.
4 of the funds FundTelligence covers report a position in Corcept Therapeutics.
- Legal name
- Corcept Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
- Exposure themes
- Cancer, Treatment, Women's Health
Funds holding Corcept Therapeutics
- DNB Fund Women's Health — DNB · 4.41 % (full portfolio disclosed, August 2026)
- DNB Global Enhanced Small Cap — DNB · 0.11 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.09 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.08 % (partially disclosed portfolio, June 2026)